Last updated: March 9, 2026
What is the drug associated with NDC 00641-6281?
NDC 00641-6281 corresponds to Remdesivir (Veklury), an antiviral medication approved by the FDA for the treatment of COVID-19. It is marketed by Gilead Sciences and became the standard of care early in the pandemic for hospitalized patients with severe disease.
How is the market for Remdesivir structured?
Market Size & Demand
- The global COVID-19 treatment market was valued at approximately USD 8 billion in 2021, with antivirals comprising a significant share.
- Recovery in COVID-19 cases and evolving treatment protocols continue to influence demand.
- The U.S. accounts for 40-45% of total sales, driven by hospital use and government procurement.
- Emergence of new variants and vaccination strategies have tempered demand growth but not eliminated the need for inpatient antiviral therapies.
Key Players
- Gilead Sciences (primary supplier)
- Generic manufacturers in emerging markets (e.g., India, Egypt)
- Hospital procurement channels, government health agencies, insurance providers
Regulatory Environment
- FDA approved Remdesivir for COVID-19 in October 2020.
- It is provided via EUA (Emergency Use Authorization) and full approval.
- Other jurisdictions (EU, Japan) have adopted similar approvals.
- Gilead maintains patent protection through 2030, with licensing agreements allowing generics in select regions.
Price history and current pricing
Historical Pricing
- Initial wholesale cost in the U.S.: approximately USD 520 per five-dose treatment course.
- Prices were set to balance affordability with R&D recovery and patent protections.
- In 2021, Gilead temporarily reduced prices in low-income countries through licensing agreements.
- Price fluctuations reflect supply chain factors, demand shifts, and policy changes.
| Year |
Average Wholesale Price (AWP) per Treatment Course |
Notes |
| 2020 |
USD 520 |
Initial launch |
| 2021 |
USD 520; discounts in licensing regions |
Gilead expands access |
| 2022 |
USD 520; variable discounts |
Market stabilization, demand plateau |
| 2023 |
Approximately USD 520; some discounts |
No significant price change since launch |
Current Pricing Trends
- No substantial price reduction observed post-2021.
- Gilead has adhered to maintaining stable pricing in the U.S. and several developed countries.
- Price discounts are prevalent in licensing regions, with margins reduced accordingly.
- Wholesaler and hospital procurement prices tend to be lower than AWP, by 20-25%.
Market projections and future outlook
Factors influencing future pricing
- Patent and exclusivity: Patent protection until 2030 limits generic competition in major markets.
- Demand fluctuations: Potential declines as vaccination rates increase and new COVID-19 treatments emerge.
- Emerging applications: Ongoing research into Remdesivir's efficacy for other viral infections could expand market size.
- Regulatory decisions: Re-evaluations by health authorities could modify approval status or mandate price adjustments.
Forecast: 2023-2028
| Year |
Projected Demand Growth |
Price Trend |
Comments |
| 2023 |
Stable; slight decline |
Stable at USD 520 per course |
Market largely stabilized |
| 2024 |
Slight decline (~5%) |
USD 495-520 range |
Competition from new COVID treatments |
| 2025 |
Stabilization |
USD 490-520 |
Patent protection persists |
| 2026 |
Potential patent expiration or licensing in emerging markets |
Relying on generic options; prices may fall significantly in these regions |
|
| 2027 |
Increased generic entry (outside major territories) |
Prices in non-patent regions decline sharply |
Potential for price erosion in low-income markets |
Key assumptions
- Patent remains unchallenged in major markets until 2030.
- No major breakthrough therapies displace Remdesivir as first-line treatment.
- Global vaccination coverage reduces severe cases, impacting demand.
Competitive landscape
- Currently, no direct generic equivalents in the U.S. due to patent exclusivity.
- Several generics authorized in India, Egypt, and other emerging markets, with prices typically 30-50% lower.
- New antiviral agents (e.g., Molnupiravir, Paxlovid) are gaining market share, though primarily for outpatient use.
Implication for investors and manufacturers
- Gilead retains pricing power in developed markets; expected to sustain USD 520 per course.
- Licensing agreements enable lower pricing in low-income markets, expanding access but reducing margins.
- Patent expiration in 2030 will significantly impact pricing and market share.
- Generics may capture substantial share post-expiration, leading to price decreases of 50% or more in certain regions.
Conclusion
Remdesivir (NDC 00641-6281) remains a central antiviral treatment for COVID-19, with stable pricing maintained by patent protection. Market demand is expected to plateau as vaccination and alternative therapies are adopted. In developed markets, prices are projected to remain around USD 520 per course until patent expiry. In emerging markets, generic competition will drive prices down over the next five years.
Key Takeaways
- Remdesivir's U.S. price has remained stable at approximately USD 520 per treatment course since launch.
- Challenges from new COVID-19 therapies and increased vaccination are limiting growth but not diminishing demand.
- Patent protection goes through 2030, with generic competition expected afterward.
- Prices in low-income countries are substantially lower due to licensing agreements, with potential for further declines.
- Market dynamics post-patent expiration will likely lead to significant price reductions and increased generic penetration.
FAQs
1. Will the price of Remdesivir decrease before patent expiry?
Price stabilization has occurred since launch; no significant reductions are forecasted until patent expiration in 2030, unless regulatory or market factors change.
2. How does the emergence of new COVID-19 treatments impact Remdesivir pricing?
New therapies like Paxlovid and Molnupiravir are shifting treatment paradigms, potentially reducing demand for Remdesivir and exerting downward pressure on its price in certain markets.
3. Are there opportunities for generic manufacturers?
Yes. Patent expiration in 2030 will open markets for generic versions, especially in regions with license agreements, significantly reducing prices.
4. How might COVID-19 variants influence demand for Remdesivir?
Variants that cause more severe illness may sustain demand; emergence of ones with milder effects could lower the necessity for inpatient antiviral therapy and reduce demand.
5. What are the key factors driving future prices?
Patent status, competition, demand levels, regulatory decisions, and regional licensing agreements will primarily shape future pricing.
References
- Gilead Sciences. (2021). Veklury (Remdesivir) product information.
- IQVIA. (2022). Pharmaceutical market report.
- U.S. Food and Drug Administration. (2020). FDA approval of Veklury for COVID-19.
- World Health Organization. (2022). COVID-19 therapeutics and vaccine impacts.
- Statista. (2023). Global COVID-19 treatment market analysis.
